BillionToOne Publishes NIPT Study Titled A Prospective, Multi-Site Study Of Performance Of Cell-Free DNA Testing For Recessive Conditions In A Large, General-Risk Pregnancy Population
BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced publication of A Prospective,
BillionToOne shared results from a big study testing their DNA technology to find rare genetic conditions in babies. This shows their test works in real situations, which helps people understand if the company's product is trustworthy.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.